What is HC Wainwright’s Forecast for ARWR FY2025 Earnings?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Analysts at HC Wainwright reduced their FY2025 EPS estimates for shares of Arrowhead Pharmaceuticals in a research note issued to investors on Wednesday, August 13th. HC Wainwright analyst P. Trucchio now expects that the biotechnology company will post earnings of ($0.20) per share for the year, down from their prior forecast of $1.57. HC Wainwright has a “Buy” rating and a $80.00 price objective on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals’ Q4 2025 earnings at $0.17 EPS, FY2026 earnings at ($2.53) EPS, FY2027 earnings at ($3.30) EPS, FY2028 earnings at ($3.20) EPS and FY2029 earnings at ($1.32) EPS.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The firm had revenue of $27.77 million for the quarter, compared to the consensus estimate of $29.01 million. During the same quarter last year, the firm posted ($1.38) EPS.

Several other research analysts also recently issued reports on the stock. Citigroup dropped their price objective on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a “neutral” rating on the stock in a report on Tuesday, May 13th. Wall Street Zen downgraded shares of Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, July 18th. Royal Bank Of Canada dropped their price objective on shares of Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an “outperform” rating on the stock in a report on Friday, August 8th. TD Cowen upgraded shares of Arrowhead Pharmaceuticals to a “strong-buy” rating in a report on Monday, July 28th. Finally, Chardan Capital restated a “buy” rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Monday, August 11th. Three equities research analysts have rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $43.14.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ:ARWR opened at $20.51 on Friday. The firm’s 50-day moving average is $16.71 and its 200-day moving average is $15.91. Arrowhead Pharmaceuticals has a 52-week low of $9.57 and a 52-week high of $27.34. The company has a debt-to-equity ratio of 0.39, a quick ratio of 4.87 and a current ratio of 4.87. The company has a market cap of $2.84 billion, a price-to-earnings ratio of -16.02 and a beta of 0.94.

Institutional Trading of Arrowhead Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Summit Investment Advisors Inc. grew its stake in Arrowhead Pharmaceuticals by 2.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 37,994 shares of the biotechnology company’s stock worth $714,000 after buying an additional 803 shares during the last quarter. Oak Ridge Investments LLC grew its stake in Arrowhead Pharmaceuticals by 2.5% during the first quarter. Oak Ridge Investments LLC now owns 33,734 shares of the biotechnology company’s stock worth $430,000 after buying an additional 823 shares during the last quarter. Resona Asset Management Co. Ltd. grew its stake in Arrowhead Pharmaceuticals by 8.7% during the second quarter. Resona Asset Management Co. Ltd. now owns 11,218 shares of the biotechnology company’s stock worth $180,000 after buying an additional 900 shares during the last quarter. Empowered Funds LLC grew its stake in Arrowhead Pharmaceuticals by 6.9% during the first quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company’s stock worth $194,000 after buying an additional 979 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in Arrowhead Pharmaceuticals by 9.0% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 14,476 shares of the biotechnology company’s stock worth $184,000 after buying an additional 1,195 shares during the last quarter. Institutional investors own 62.61% of the company’s stock.

Insiders Place Their Bets

In related news, insider James C. Hamilton sold 9,389 shares of the company’s stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $20.00, for a total value of $187,780.00. Following the sale, the insider owned 262,122 shares of the company’s stock, valued at $5,242,440. The trade was a 3.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 4.30% of the stock is currently owned by insiders.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.